{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:38:50Z","timestamp":1784299130351,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00210-024-03746-9","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T06:38:58Z","timestamp":1736923138000},"page":"8469-8477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1007","volume":"398","author":[{"given":"Bahram","family":"Shahri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid Reza","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Jarahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shariatikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vafa","family":"Baradaran Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"3746_CR1","first-page":"e52747","volume":"16","author":"JA Ahmed","year":"2024","unstructured":"Ahmed JA, Ahmed KA, Ahmed MH (2024) Ranolazine as a first-choice anti-anginal medication for patients with coronary artery ectasia: a case series. Cureus 16:e52747","journal-title":"Cureus"},{"key":"3746_CR2","doi-asserted-by":"publisher","first-page":"e08","DOI":"10.15420\/ecr.2021.46","volume":"17","author":"A Aparicio","year":"2022","unstructured":"Aparicio A, Cuevas J, Mor\u00eds C, Mart\u00edn M (2022) Slow coronary blood flow: pathogenesis and clinical implications. Eur Cardiol 17:e08","journal-title":"Eur Cardiol"},{"key":"3746_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jacc.2004.03.055","volume":"44","author":"JF Beltrame","year":"2004","unstructured":"Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD (2004) The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol 44:57\u201362","journal-title":"J Am Coll Cardiol"},{"key":"3746_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jval.2022.01.017","volume":"25","author":"R Blythe","year":"2022","unstructured":"Blythe R, White N, Kularatna S, McPhail S, Barnett A (2022) A Bayesian approach for Incorporating the EQ-5D visual analog scale when estimating the health-related quality of life. Value in Health 25:1575\u20131581","journal-title":"Value in Health"},{"key":"3746_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/00033197211004390","volume":"72","author":"G Chalikias","year":"2021","unstructured":"Chalikias G, Tziakas D (2021) Slow Coronary flow: pathophysiology, clinical implications, and therapeutic management. Angiology 72:808\u2013818","journal-title":"Angiology"},{"key":"3746_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41416-024-02622-w","volume":"130","author":"MBA Djamgoz","year":"2024","unstructured":"Djamgoz MBA (2024) Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels. Br J Cancer 130:1415\u20131419","journal-title":"Br J Cancer"},{"key":"3746_CR7","doi-asserted-by":"crossref","unstructured":"Ermawan R, Pintaningrum Y, Indrayana Y (2024) The predictors of coronary slow flow in patients undergoing coronary angiography. Egypt Heart J 76:103","DOI":"10.1186\/s43044-024-00536-9"},{"key":"3746_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1590\/S0066-782X2011005000105","volume":"97","author":"Y Gunes","year":"2011","unstructured":"Gunes Y, Gumrukcuoglu HA, Akdag S, Simsek H, Sahin M, Tuncer M (2011) Vascular endothelial function in patients with coronary slow flow and the effects of nebivolol. Arq Bras Cardiol 97:275\u2013280","journal-title":"Arq Bras Cardiol"},{"key":"3746_CR9","doi-asserted-by":"publisher","first-page":"e24643","DOI":"10.1097\/MD.0000000000024643","volume":"100","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zhang F, Chen S, Dong Z, Liu W, Zhou X (2021) Clinical characteristics in patients with coronary slow flow phenomenon: a retrospective study. Medicine (Baltimore) 100:e24643","journal-title":"Medicine (Baltimore)"},{"key":"3746_CR10","doi-asserted-by":"publisher","first-page":"e15513","DOI":"10.14814\/phy2.15513","volume":"10","author":"R KhamenehBagheri","year":"2022","unstructured":"KhamenehBagheri R, Najafi MN, Ahmadi M, Saberi M, Maleki M, BaradaranRahimi V (2022) Investigation of the association between serum uric acid levels and HEART risk score in patients with acute coronary syndrome. Physiol Rep 10:e15513","journal-title":"Physiol Rep"},{"key":"3746_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1751-7176.2010.00401.x","volume":"13","author":"H Lethen","year":"2011","unstructured":"Lethen H, Tries HP, Kersting S, Bramlage P, Lambertz H (2011) Improvement of coronary microvascular function after Angiotensin receptor blocker treatment with irbesartan in patients with systemic hypertension. J Clin Hypertens (Greenwich) 13:155\u2013161","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3746_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjms.2023.12.001","volume":"367","author":"A Manolis","year":"2024","unstructured":"Manolis A, Kallistratos M, Poulimenos L, Thomopoulos C (2024) Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes. Am J Med Sci 367:155\u2013159","journal-title":"Am J Med Sci"},{"key":"3746_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccas.2019.11.059","volume":"2","author":"V Mart\u00ednezPereyra","year":"2020","unstructured":"Mart\u00ednezPereyra V, Seitz A, Hubert A, Mahrholdt H, Bekeredjian R, Sechtem U, Ong P (2020) Coronary microvascular spasm as the underlying cause of the angiographic slow flow phenomenon. JACC Case Rep 2:35\u201339","journal-title":"JACC Case Rep"},{"key":"3746_CR14","doi-asserted-by":"crossref","unstructured":"Mehta HH, Morris M, Fischman DL, Finley JJt, Ruggiero N, Walinsky P, McCarey M, Savage MP (2019) The spontaneous coronary slow-flow phenomenon: reversal by intracoronary nicardipine. J Invasive Cardiol 31:42-45","DOI":"10.25270\/jic\/18.00250"},{"key":"3746_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","volume":"4","author":"PK Mehta","year":"2011","unstructured":"Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, Gill E, Minissian M, Shaw LJ, Slomka PJ, Slivka M, Berman DS, BaireyMerz CN (2011) Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 4:514\u2013522","journal-title":"JACC Cardiovasc Imaging"},{"key":"3746_CR16","doi-asserted-by":"publisher","first-page":"11587","DOI":"10.1002\/jcp.27791","volume":"234","author":"J Nie","year":"2019","unstructured":"Nie J, Duan Q, He M, Li X, Wang B, Zhou C, Wu L, Wen Z, Chen C, Wang DW, Alsina KM, Wehrens XHT, Wang DW, Ni L (2019) Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na(+) and Ca(2+) handling. J Cell Physiol 234:11587\u201311601","journal-title":"J Cell Physiol"},{"key":"3746_CR17","doi-asserted-by":"publisher","first-page":"1207580","DOI":"10.3389\/fcvm.2023.1207580","volume":"10","author":"D Oksen","year":"2023","unstructured":"Oksen D, Aslan M, Ozmen E, Yavuz YE (2023) Ranolazine improved left ventricular diastolic functions and ventricular repolarization indexes in patients with coronary slow flow. Front Cardiovasc Med 10:1207580","journal-title":"Front Cardiovasc Med"},{"key":"3746_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2020.02.014","volume":"309","author":"VS Pargaonkar","year":"2020","unstructured":"Pargaonkar VS, Tremmel JA, Schnittger I, Khandelwal A (2020) Effect of ranolazine on symptom and quality of life in patients with angina in the absence of obstructive coronary artery disease: a case control study. Int J Cardiol 309:8\u201313","journal-title":"Int J Cardiol"},{"key":"3746_CR19","doi-asserted-by":"publisher","first-page":"5945101","DOI":"10.1155\/2021\/5945101","volume":"2021","author":"P Rahmanian-Devin","year":"2021","unstructured":"Rahmanian-Devin P, Rakhshandeh H, BaradaranRahimi V, Sanei-Far Z, Hasanpour M, Memarzia A, Iranshahi M, Askari VR (2021) Intraperitoneal lavage with crocus sativus prevents postoperative-induced peritoneal adhesion in a rat model: evidence from animal and cellular studies. Oxid Med Cell Longev 2021:5945101","journal-title":"Oxid Med Cell Longev"},{"key":"3746_CR20","doi-asserted-by":"crossref","unstructured":"Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, Mejia Dolores JW, Rey Rodriguez DE, Loza Mun\u00e1rriz C (2017) Ranolazine for stable angina pectoris. Cochrane Database Syst Rev 2:Cd011747","DOI":"10.1002\/14651858.CD011747.pub2"},{"issue":"Suppl 3","key":"3746_CR21","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.ihj.2018.06.001","volume":"70","author":"S Sanghvi","year":"2018","unstructured":"Sanghvi S, Mathur R, Baroopal A, Kumar A (2018) Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: a single centre experience. Indian Heart J 70(Suppl 3):S290-s294","journal-title":"Indian Heart J"},{"key":"3746_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/1074248415571457","volume":"20","author":"HD Sani","year":"2015","unstructured":"Sani HD, Eshraghi A, Nezafati MH, Vojdanparast M, Shahri B, Nezafati P (2015) Nicorandil Versus nitroglycerin for symptomatic relief of angina in patients with slow coronary flow phenomenon: a randomized clinical trial. J Cardiovasc Pharmacol Ther 20:401\u2013406","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"3746_CR23","first-page":"343027","volume":"2013","author":"A Santoro","year":"2013","unstructured":"Santoro A, SchianoLomoriello V, Santoro C, Muscariello R, Galderisi M (2013) Resolution of angina pectoris and improvement of the coronary flow reserve after ranolazine treatment in a woman with isolated impaired coronary microcirculation. Case Rep Cardiol 2013:343027","journal-title":"Case Rep Cardiol"},{"key":"3746_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40256-020-00462-6","volume":"21","author":"RP Sharp","year":"2021","unstructured":"Sharp RP, Patatanian E, Sirajuddin R (2021) Use of ranolazine for the treatment of coronary microvascular dysfunction. Am J Cardiovasc Drugs 21:513\u2013521","journal-title":"Am J Cardiovasc Drugs"},{"key":"3746_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3831\/KPI.2019.22.002","volume":"22","author":"R Shirazinia","year":"2019","unstructured":"Shirazinia R, Rahimi VB, Kehkhaie AR, Sahebkar A, Rakhshandeh H, Askari VR (2019) Opuntia dillenii: a forgotten plant with promising pharmacological properties. J Pharmacopuncture 22:16\u201327","journal-title":"J Pharmacopuncture"},{"key":"3746_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s13063-024-08354-9","volume":"25","author":"M Soltani","year":"2024","unstructured":"Soltani M, Hosseinzadeh-Attar MJ, Rezaei M, Alipoor E, Vasheghani-Farahani A, Yaseri M, Rezayat SM (2024) Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial. Trials 25:515","journal-title":"Trials"},{"key":"3746_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamacardio.2020.7478","volume":"6","author":"M Thomas","year":"2021","unstructured":"Thomas M, Jones PG, Arnold SV, Spertus JA (2021) Interpretation of the Seattle Angina Questionnaire as an outcome measure in clinical trials and clinical care: a review. JAMA Cardiol 6:593\u2013599","journal-title":"JAMA Cardiol"},{"key":"3746_CR28","first-page":"367","volume":"40","author":"T Vairaperumal","year":"2024","unstructured":"Vairaperumal T, Tsai ZY, Liu PY (2024) Emerging predictors by Non-HDL-C\/HDL-C ratio and novel biomarkers for coronary slow flow phenomenon. Acta Cardiol Sin 40:367\u2013372","journal-title":"Acta Cardiol Sin"},{"key":"3746_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","volume":"112","author":"A Villano","year":"2013","unstructured":"Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, Di Monaco A, Sarullo FM, Lanza GA, Crea F (2013) Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 112:8\u201313","journal-title":"Am J Cardiol"},{"key":"3746_CR30","first-page":"37","volume":"1","author":"X Wang","year":"2011","unstructured":"Wang X, Nie SP (2011) The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther 1:37\u201343","journal-title":"Cardiovasc Diagn Ther"},{"key":"3746_CR31","doi-asserted-by":"publisher","first-page":"580419","DOI":"10.3389\/fcvm.2020.580419","volume":"7","author":"J Yong","year":"2020","unstructured":"Yong J, Tian J, Yang X, Xing H, He Y, Song X (2020) Effects of oral drugs on coronary microvascular function in patients without significant stenosis of epicardial coronary arteries: a systematic review and meta-analysis of coronary flow reserve. Front Cardiovasc Med 7:580419","journal-title":"Front Cardiovasc Med"},{"key":"3746_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tcm.2022.12.001","volume":"34","author":"Q Zhu","year":"2024","unstructured":"Zhu Q, Wang S, Huang X, Zhao C, Wang Y, Li X, Jia D, Ma C (2024) Understanding the pathogenesis of coronary slow flow: recent advances. Trends Cardiovasc Med 34:137\u2013144","journal-title":"Trends Cardiovasc Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03746-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:19:04Z","timestamp":1757128744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03746-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03746-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval has been granted for this investigation by Mashhad University of Medical Sciences (confirmation code: IR.MUMS.MEDICAL.REC.1401.291). Additionally, the trial has been assigned an ID number at  (code. IRCT20220516054874N6).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants in writing and signed by them.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The manuscript is approved by all authors for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}